Drug Trial Radar · NCT06208410
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
306
Planned (sponsor's estimate)
Start
Jan 11, 2024
Primary completion
Feb 26, 2027
Study completion Feb 26, 2027
Sponsor
- Lead sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.
Conditions
- Advanced Solid Tumors
Interventions
JS105Drug
JS105 is administered once daily, orally
Fulvestrant injectionDrug
Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
Dalpiciclib Isetionate TabletsDrug
Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
Toripalimab InjectionDrug
Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
Paclitaxel for Injection (Albumin Bound)Drug
Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
Fluzoparib CapsulesDrug
Fluzoparib Capsules is administered once daily, orally
Pyrotinib Maleate TabletsDrug
Pyrotinib Maleate Tablets is administered once daily, orally
Capecitabine TabletsDrug
Capecitabine Tablets is administered once daily, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: At the end of Cycle 1 (each cycle is 28 days)
- MTDTime frame: At the end of Cycle 1 (each cycle is 28 days)
- RP2DTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Incidence and severity of adverse events including serious adverse eventsTime frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Provincial Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.